Medication | Dose form | 0 to 4 years | 5 to 11 years | Comments |
Combined inhaled glucocorticoids and long-acting beta agonists (LABAs)¶ | ||||
Budesonide-formoterol | MDI 80 mcg/4.5 mcg per actuation | Safety and efficacy not established.Δ | Low-dose ICS-LABA: 1 inhalation once or twice per day. Medium-dose ICS-LABA: 2 inhalations twice per day. |
|
Mometasone-formoterol | MDI 50 mcg/5 mcg per actuation | Safety and efficacy not established.Δ | Low- to medium-dose ICS-LABA: 1 inhalation twice per day. High-dose ICS-LABA: 2 inhalations twice per day. | |
Fluticasone furoate-vilanterol◊ | DPI 50 mcg/25 mcg per actuation | Safety and efficacy not established. | Low- to medium-dose ICS-LABA: 1 inhalation once per day. |
|
Fluticasone propionate-salmeterol | DPI 100 mcg/50 mcg per actuation | Safety and efficacy not established. | Medium-dose ICS-LABA: 1 inhalation twice per day (4 to 11 years of age). | |
MDI 45 mcg/21 mcg per actuation | Safety and efficacy not established.Δ§ | Low-dose ICS-LABA: 1 inhalation twice per day. Medium-dose ICS-LABA: 2 inhalations twice per day. | ||
Leukotriene receptor antagonists (LTRAs)¥ | ||||
Montelukast | 4 mg or 5 mg chewable tablet 4 mg granule packets | 4 mg once daily at bedtime (1 to 5 years of age). | 5 mg once daily at bedtime (6 to 14 years of age). |
|
Zafirlukast | 10 mg tablet | Safety and efficacy not established. | 10 mg twice per day on empty stomach. |
|
Systemic glucocorticoids | ||||
Methylprednisolone Prednisolone Prednisone | For detail, refer to drug-specific monographs included with UpToDate | 0.25 to 2 mg/kg orally per day or every other day given in the morning. Titrate to the lowest acceptable dose that maintains control. | 0.25 to 2 mg/kg orally per day or every other day given in the morning. Titrate to the lowest acceptable dose that maintains control. | (Applies to all 3 glucocorticoids)
|
Long-acting anticholinergic agents | ||||
Tiotropium | Soft-mist inhaler 1.25 mcg/actuation | Safety and efficacy not established. | 2 inhalations once daily (≥6 years of age). (Off-label use: 2 inhalations of 2.5 mcg/actuation dose once daily.) |
|
Chromones | ||||
Cromolyn sodium (sodium cromoglycate) | CFC-free MDI (not available in the United States)†:
| Safety and efficacy not established. | 1 mg/actuation: 2 inhalations 4 times per day. 5 mg/actuation: 2 inhalations twice per day. |
|
20 mg/ampule solution for nebulization | 20 mg 4 times per day. Safety and efficacy not established in children aged <2 years. | 20 mg 4 times per day. | ||
Biologic agents: Refer to separate UpToDate table and topics on biologic therapy for asthma, including omalizumab (anti-IgE) and mepolizumab (anti-IL-5) | ||||
Methylxanthines | ||||
Theophylline | Liquids, sustained-release tablets and capsules | Starting dose for patients without risk factors for decreased theophylline clearance approximately 10 mg/kg per day (initial maximum 300 mg per day). Usual maximum following titration:
| Starting dose for patients without risk factors for decreased theophylline clearance approximately 10 mg/kg/day (initial maximum 300 mg per day). Usual maximum following titration:
|
|
CFC: chlorofluorocarbon; DPI: dry-powder inhaler; GINA: Global Initiative for Asthma; ICS: inhaled corticosteroid (glucocorticoid); IgE: immunoglobulin E; IL: interleukin; LABA: long-acting beta agonist; LTRA: leukotriene receptor antagonist; MDI: metered-dose inhaler; NAEPP: National Asthma Education and Prevention Program; SMART: single maintenance and reliever therapy.
* Doses are provided for medications with sufficient clinical trial safety and efficacy data in the appropriate age ranges to support their use.[1,2] Some doses may not be approved by regulatory bodies (ie, are used "off label"); refer to local prescribing information for approved uses.
¶ LABAs should only be used in combination products with inhaled glucocorticoids. Other ICS-LABA combination products are available. Some ICS-LABA combination inhalers may be approved for use in children in countries other than the United States. ICS dose range is according to GINA.[2]
Δ The NAEPP expert panel guidelines[1] and UpToDate authors suggest ICS-LABA therapy in patients ≤4 years of age depending on symptom severity; however, dosing has not been established, and safety and efficacy data are limited. For patients in this age range who would benefit from ICS-LABA therapy, may consider doses provided for 5- to 11-year-old patients.
◊ Inhaled fluticasone furoate has a greater antiinflammatory potency per microgram than fluticasone propionate inhalers. Thus, fluticasone furoate is administered at a lower daily dose and used only once daily.
§ Based on efficacy data of the fluticasone MDI in young children and expected lower dose to be delivered with a facemask, fluticasone propionate-salmeterol 45 mcg/21 mcg 2 inhalations twice per day may be categorized as low-dose ICS therapy in patients <4 years of age.[3]
¥ Zileuton is available in the United States and some other countries. Its use is not recommended in children.
‡ Monitoring of transaminases to screen for liver injury has not been shown to be effective in preventing rare hepatic injury due to zafirlukast, and the optimal timing and frequency of testing is not well defined. If liver dysfunction is suspected based on clinical signs or symptoms, immediately discontinue zafirlukast and evaluate for drug-induced liver injury.
† Chromone DPI and MDI inhalers with different strengths than those listed in this table are available in some countries other than the United States. Consult local product information.